Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis

Samira M. Sadowski, Myriem Boufraqech, Lisa Zhang, Amit Mehta, Payal Kapur, Yaqin Zhang, Zhuyin Li, Min Shen, Electron Kebebew

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Anaplastic thyroid cancer (ATC) is rare but it is one of the most lethal human malignancies with no effective therapy. There is a pressing need to identify new therapeutic agents for ATC. We performed quantitative high-throughput screening (qHTS) in ATC cell lines using a compound library of 3,282 drugs. qHTS identified 100 pan-active agents. Enrichment analysis of qHTS data showed drugs targeting mTOR were one of the most active drug categories, and Torin2 showed the highest efficacy. We found mTOR to be upregulated in ATC. Treatment of multiple ATC cell lines with Torin2 showed significant dose-dependent inhibition of cellular proliferation with caspase-dependent apoptosis and G1/S phase arrest. Torin2 inhibited cellular migration and inhibited the phosphorylation of key effectors of the mTOR-pathway (AKT, 4E-BP1 and 70S6K), as well as claspin and survivin expression, regulators of cell cycle and apoptosis. In our in vivo mouse model of metastatic ATC, Torin2 inhibited tumor growth and metastasis and significantly prolonged overall survival. Our findings suggest that Torin2 is a promising agent for ATC therapy and that it effectively targets upregulated pathways in human ATC.

Original languageEnglish (US)
Pages (from-to)18038-18049
Number of pages12
JournalOncotarget
Volume6
Issue number20
StatePublished - 2015

Fingerprint

Neoplasm Metastasis
Growth
Neoplasms
Apoptosis
Cell Line
Anaplastic Thyroid Carcinoma
G1 Phase
Therapeutics
Drug Delivery Systems
Caspases
S Phase
Pharmaceutical Preparations
Cell Cycle
Phosphorylation
Cell Proliferation
Survival

Keywords

  • Anaplastic thyroid cancer
  • mTOR
  • mTORC1 inhibitor
  • Quantitative high-troughput screening
  • Torin2

ASJC Scopus subject areas

  • Oncology

Cite this

Sadowski, S. M., Boufraqech, M., Zhang, L., Mehta, A., Kapur, P., Zhang, Y., ... Kebebew, E. (2015). Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget, 6(20), 18038-18049.

Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. / Sadowski, Samira M.; Boufraqech, Myriem; Zhang, Lisa; Mehta, Amit; Kapur, Payal; Zhang, Yaqin; Li, Zhuyin; Shen, Min; Kebebew, Electron.

In: Oncotarget, Vol. 6, No. 20, 2015, p. 18038-18049.

Research output: Contribution to journalArticle

Sadowski, SM, Boufraqech, M, Zhang, L, Mehta, A, Kapur, P, Zhang, Y, Li, Z, Shen, M & Kebebew, E 2015, 'Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis', Oncotarget, vol. 6, no. 20, pp. 18038-18049.
Sadowski SM, Boufraqech M, Zhang L, Mehta A, Kapur P, Zhang Y et al. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget. 2015;6(20):18038-18049.
Sadowski, Samira M. ; Boufraqech, Myriem ; Zhang, Lisa ; Mehta, Amit ; Kapur, Payal ; Zhang, Yaqin ; Li, Zhuyin ; Shen, Min ; Kebebew, Electron. / Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. In: Oncotarget. 2015 ; Vol. 6, No. 20. pp. 18038-18049.
@article{eaae88356abe43eda40079e574910139,
title = "Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis",
abstract = "Anaplastic thyroid cancer (ATC) is rare but it is one of the most lethal human malignancies with no effective therapy. There is a pressing need to identify new therapeutic agents for ATC. We performed quantitative high-throughput screening (qHTS) in ATC cell lines using a compound library of 3,282 drugs. qHTS identified 100 pan-active agents. Enrichment analysis of qHTS data showed drugs targeting mTOR were one of the most active drug categories, and Torin2 showed the highest efficacy. We found mTOR to be upregulated in ATC. Treatment of multiple ATC cell lines with Torin2 showed significant dose-dependent inhibition of cellular proliferation with caspase-dependent apoptosis and G1/S phase arrest. Torin2 inhibited cellular migration and inhibited the phosphorylation of key effectors of the mTOR-pathway (AKT, 4E-BP1 and 70S6K), as well as claspin and survivin expression, regulators of cell cycle and apoptosis. In our in vivo mouse model of metastatic ATC, Torin2 inhibited tumor growth and metastasis and significantly prolonged overall survival. Our findings suggest that Torin2 is a promising agent for ATC therapy and that it effectively targets upregulated pathways in human ATC.",
keywords = "Anaplastic thyroid cancer, mTOR, mTORC1 inhibitor, Quantitative high-troughput screening, Torin2",
author = "Sadowski, {Samira M.} and Myriem Boufraqech and Lisa Zhang and Amit Mehta and Payal Kapur and Yaqin Zhang and Zhuyin Li and Min Shen and Electron Kebebew",
year = "2015",
language = "English (US)",
volume = "6",
pages = "18038--18049",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis

AU - Sadowski, Samira M.

AU - Boufraqech, Myriem

AU - Zhang, Lisa

AU - Mehta, Amit

AU - Kapur, Payal

AU - Zhang, Yaqin

AU - Li, Zhuyin

AU - Shen, Min

AU - Kebebew, Electron

PY - 2015

Y1 - 2015

N2 - Anaplastic thyroid cancer (ATC) is rare but it is one of the most lethal human malignancies with no effective therapy. There is a pressing need to identify new therapeutic agents for ATC. We performed quantitative high-throughput screening (qHTS) in ATC cell lines using a compound library of 3,282 drugs. qHTS identified 100 pan-active agents. Enrichment analysis of qHTS data showed drugs targeting mTOR were one of the most active drug categories, and Torin2 showed the highest efficacy. We found mTOR to be upregulated in ATC. Treatment of multiple ATC cell lines with Torin2 showed significant dose-dependent inhibition of cellular proliferation with caspase-dependent apoptosis and G1/S phase arrest. Torin2 inhibited cellular migration and inhibited the phosphorylation of key effectors of the mTOR-pathway (AKT, 4E-BP1 and 70S6K), as well as claspin and survivin expression, regulators of cell cycle and apoptosis. In our in vivo mouse model of metastatic ATC, Torin2 inhibited tumor growth and metastasis and significantly prolonged overall survival. Our findings suggest that Torin2 is a promising agent for ATC therapy and that it effectively targets upregulated pathways in human ATC.

AB - Anaplastic thyroid cancer (ATC) is rare but it is one of the most lethal human malignancies with no effective therapy. There is a pressing need to identify new therapeutic agents for ATC. We performed quantitative high-throughput screening (qHTS) in ATC cell lines using a compound library of 3,282 drugs. qHTS identified 100 pan-active agents. Enrichment analysis of qHTS data showed drugs targeting mTOR were one of the most active drug categories, and Torin2 showed the highest efficacy. We found mTOR to be upregulated in ATC. Treatment of multiple ATC cell lines with Torin2 showed significant dose-dependent inhibition of cellular proliferation with caspase-dependent apoptosis and G1/S phase arrest. Torin2 inhibited cellular migration and inhibited the phosphorylation of key effectors of the mTOR-pathway (AKT, 4E-BP1 and 70S6K), as well as claspin and survivin expression, regulators of cell cycle and apoptosis. In our in vivo mouse model of metastatic ATC, Torin2 inhibited tumor growth and metastasis and significantly prolonged overall survival. Our findings suggest that Torin2 is a promising agent for ATC therapy and that it effectively targets upregulated pathways in human ATC.

KW - Anaplastic thyroid cancer

KW - mTOR

KW - mTORC1 inhibitor

KW - Quantitative high-troughput screening

KW - Torin2

UR - http://www.scopus.com/inward/record.url?scp=84938632401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938632401&partnerID=8YFLogxK

M3 - Article

C2 - 25945839

AN - SCOPUS:84938632401

VL - 6

SP - 18038

EP - 18049

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -